Alkermes PLC (ALKS)
23.88
-0.12
(-0.52%)
USD |
NASDAQ |
Apr 16, 13:16
Alkermes Research and Development Expense (Quarterly): -20.76M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -20.76M |
| September 30, 2023 | 97.14M |
| June 30, 2023 | 100.79M |
| March 31, 2023 | 93.64M |
| December 31, 2022 | -16.55M |
| September 30, 2022 | 100.43M |
| June 30, 2022 | 92.87M |
| March 31, 2022 | 95.95M |
| December 31, 2021 | -17.23M |
| September 30, 2021 | 118.41M |
| June 30, 2021 | 97.47M |
| March 31, 2021 | 92.27M |
| December 31, 2020 | 112.11M |
| September 30, 2020 | 94.98M |
| June 30, 2020 | 94.22M |
| March 31, 2020 | 93.28M |
| December 31, 2019 | 198.16M |
| September 30, 2019 | 107.67M |
| June 30, 2019 | 104.44M |
| March 31, 2019 | 102.57M |
| December 31, 2018 | 108.97M |
| September 30, 2018 | 101.26M |
| June 30, 2018 | 106.82M |
| March 31, 2018 | 108.35M |
| December 31, 2017 | 104.49M |
| Date | Value |
|---|---|
| September 30, 2017 | 104.41M |
| June 30, 2017 | 99.15M |
| March 31, 2017 | 104.84M |
| December 31, 2016 | 89.62M |
| September 30, 2016 | 99.44M |
| June 30, 2016 | 97.01M |
| March 31, 2016 | 101.07M |
| December 31, 2015 | 93.69M |
| September 30, 2015 | 92.56M |
| June 30, 2015 | 87.88M |
| March 31, 2015 | 70.28M |
| December 31, 2014 | 74.43M |
| September 30, 2014 | 78.26M |
| June 30, 2014 | 67.21M |
| March 31, 2014 | 52.14M |
| September 30, 2013 | 45.95M |
| June 30, 2013 | 33.46M |
| March 31, 2013 | 35.80M |
| December 31, 2012 | 31.32M |
| September 30, 2012 | 35.09M |
| June 30, 2012 | 37.81M |
| March 31, 2012 | 45.19M |
| December 31, 2011 | 40.49M |
| September 30, 2011 | 28.16M |
| June 30, 2011 | 28.05M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-20.76M
Minimum
Dec 2023
198.16M
Maximum
Dec 2019
86.28M
Average
95.95M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Endo International PLC | 28.14M |
| Jazz Pharmaceuticals PLC | 216.61M |
| Medtronic PLC | 695.00M |
| Perrigo Co PLC | 29.60M |
| Iterum Therapeutics PLC | 9.744M |